Omeprazole/sodium bicarbonate
ApprovedCompleted 0 watching 0 views this week🔥 Hot
80
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Erosive Esophagitis
Conditions
Erosive Esophagitis
Trial Timeline
Jan 1, 2008 → Dec 1, 2010
NCT ID
NCT00693225About Omeprazole/sodium bicarbonate
Omeprazole/sodium bicarbonate is a approved stage product being developed by Bausch Health for Erosive Esophagitis. The current trial status is completed. This product is registered under clinical trial identifier NCT00693225. Target conditions include Erosive Esophagitis.
Hype Score Breakdown
Clinical
30
Activity
20
Company
5
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00693225 | Approved | Completed |
Competing Products
20 competing products in Erosive Esophagitis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| YH1885L(Revaprazan) + Esomeprazole 20mg + placebo | Yuhan | Phase 2 | 52 |
| E3810 + E3810 + Placebo | Eisai | Phase 3 | 77 |
| RABEPRAZOLE SODIUM + RABEPRAZOLE SODIUM | Eisai | Phase 3 | 77 |
| Teprenone capsule and placebo of sucralfate + Sucralfate and placebo of teprenone | Eisai | Approved | 85 |
| ABT-981 + Placebo for ABT-981 | AbbVie | Phase 2 | 52 |
| Omeprazole | AstraZeneca | Phase 3 | 77 |
| Esomeprazole + Lansoprazole | AstraZeneca | Approved | 85 |
| Nexium 20mg + Nexium 10mg | AstraZeneca | Phase 3 | 77 |
| Omeprazole | AstraZeneca | Phase 3 | 77 |
| AZD0865 | AstraZeneca | Phase 2 | 52 |
| Esomeprazole + Lansoprazole | AstraZeneca | Approved | 85 |
| Esomeprazole + Esomeprazole | AstraZeneca | Approved | 85 |
| AZD0865 | AstraZeneca | Phase 2 | 52 |
| esomeprazole magnesium (oral medication) | AstraZeneca | Approved | 85 |
| Alendronate Effervescent Oral Tablet | Amgen | Phase 2 | 51 |
| Vonoprazan | Phathom Pharmaceuticals | Phase 1 | 28 |
| Vonoprazan + Lansoprazole | Phathom Pharmaceuticals | Phase 3 | 72 |
| Vonoprazan + Placebo | Phathom Pharmaceuticals | Phase 2 | 47 |
| Vonoprazan | Phathom Pharmaceuticals | Pre-clinical | 18 |
| Vonoprazan + Placebo | Phathom Pharmaceuticals | Phase 3 | 72 |